Saturday, 10 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

INVENTIVA Stock 13.4% Up Today

Loading stream...

(vianews) - the market ended the session with inventiva (iva.pa) rising 13.4% to €2.84 on monday while cac 40 fell 0.21% to €7,303.81.

about inventiva

inventiva s.a., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (nash) and other diseases. its lead product candidate is lanifibranor, which is in phase iii clinical trial to treat nash. the company also develops odiparcil, which has completed phase iia clinical trial for the treatment of mucopolysaccharidoses type vi disease. in addition, it has a pipeline of earlier stage programs in oncology and other diseases. the company was founded in 2011 and is headquartered in daix, france.

earnings per share

as for profitability, inventiva has a trailing twelve months eps of €-1.2.

more news about inventiva (iva.pa).

Categories

stockMarket

Tags

INVENTIVAMarket-Close NowIVA.PAStock PriceClosesStock Market NowEnd of DayPrice UpMarket CloseStock Price UpStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com